SOMA GOLD SUBSIDIARY ACHIEVES CARBON NEUTRALITY - A FIRST IN COLOMBIAN MINING
The carbon neutrality certification, issued by Bureau Veritas – BVQI Colombia Ltd., is the result of a multi-year effort focused on measuring, reducing, and offsetting greenhouse gas (GHG) emissions. Operadora's sustainability strategy includes a transition to 100% renewable hydroelectric power, major operational efficiencies, and verified offsets through REDD+ projects in the Amazon rainforest.
Héctor Meléndez, Soma's Colombia Country Manager, states, "We are proud to be the first mining company in Colombia to achieve carbon neutrality. This achievement proves that mining can be part of the solution to the global climate challenge and reinforces our commitment to environmental leadership."
Highlights of the Carbon Neutrality Milestone:
66% reduction in GHG emissions since 2021, equal to 2,812 tons of CO₂e.
Remaining emissions – totaling 1,345 t CO₂e in 2023 – fully offset using externally verified first-class carbon credits.
The entire process was independently verified and certified by Bureau Veritas.
A Voluntary Alliance for Regeneration
In addition to achieving carbon neutrality, Operadora Minera has signed a voluntary agreement with CORANTIOQUIA, alongside three formalized small-scale miners, to promote environmental regeneration in areas affected by illegal mining. This agreement aims to restore ecosystems, rehabilitate water sources, reforest degraded land, and promote biodiversity through sustainable practices and education programs.
"This agreement reflects our life-centric values and our commitment to leaving a lasting legacy of environmental stewardship," said Héctor Meléndez. "We are proud to partner with local communities and environmental authorities to create a healthier future."
These achievements underscore Soma's long-term commitment to responsible mining, aligning with its strategy to reduce environmental impact, support biodiversity, and deliver long-term value to local communities.
Héctor Meléndez, Soma's Colombia Country Manager, states: "This milestone reflects the dedication and integrity of our entire team in Colombia. Achieving carbon neutrality across multiple emission scopes is no small feat. It's the result of years of hard work, innovation, and a shared vision for sustainable mining. I'm incredibly proud of what we've accomplished together."
ABOUT SOMA GOLD
Soma Gold Corp. (TSXV: SOMA) is a mining company focused on gold production and exploration. The Company owns two adjacent mining properties in Antioquia, Colombia, with a combined milling capacity of 675 tpd. (Permitted for 1,400 tpd). The El Bagre Mill is currently operating and producing. Internally generated funds are being used to finance a regional exploration program.
With a solid commitment to sustainability and community engagement, Soma Gold Corp. is dedicated to achieving excellence in all aspects of its operations.
The Company also owns an exploration property near Tucuma, Para State, Brazil that is currently under option to Ero Copper Corp.
On behalf of the Board of Directors
"Geoff Hampson"Chief Executive Officer and President
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
All statements, analysis and other information contained in this press release about anticipated future events or results constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking statements are subject to business and economic risks and uncertainties and other factors that could cause actual results of operations to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.
SOURCE Soma Gold Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/15/c7497.html
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 minutes ago
- Business Wire
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress
SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the 'Company', 'Arcturus', Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced its financial results for the second quarter ended June 30, 2025, and provided corporate updates. 'The Company continues to advance and provide meaningful clinical data across our mRNA therapeutics and vaccines pipeline,' said Joseph Payne, President & CEO of Arcturus Therapeutics. 'We are especially pleased with the recent proof-of-concept in our liver platform based on the positive ARCT-810 interim Phase 2 data and look forward to sharing two cohorts of Phase 2 CF data in September.' Recent Corporate Highlights Arcturus is advancing enrollment of adult CF participants in the open label Phase 2 multiple ascending dose CF study (NCT06747858) with daily inhaled treatments of ARCT-032 over a period of 28 days and expects to complete enrollment as planned by year end. All six participants in the second cohort (10 mg) are expected to complete dosing in early September. The Company expects to provide Phase 2 interim data from the first nine enrolled participants (N = 3 @ 5 mg; N = 6 @ 10 mg) in September 2025. The Company anticipates meetings with the FDA and other regulatory agencies in H1 2026 to discuss the Phase 2 data and plans for pivotal trials, including the enrollment of adolescent and pediatric participants, followed by Phase 3 initiation in 2026. In June, the company announced positive interim data from two Phase 2 multiple dose studies conducted in the OTC program. In each study and in combined analyses of both Phase 2 studies, decreases in glutamine levels to within normal range were observed following multiple ARCT-810 administrations to participants who remained on their standard of care therapy. Mean ammonia levels were stable within the normal range following at least two doses of ARCT-810 and remained stable for approximately 28 days after completion of dosing. During the treatment phase and follow-up, two out of three participants in the Phase 2 U.S. study (NCT06488313) showed increases in relative ureagenesis function to levels observed in asymptomatic OTC deficient patients (≥ 50% of healthy controls) as measured by a newly developed and optimized 15N-ureagenesis assay. The remaining participant demonstrated increased 15N-citrulline enrichment. The data, taken together, suggest improvement of urea cycle function in all 3 participants. ARCT-810 was generally safe and well tolerated in single dose Phase 1/1b and multi-dose Phase 2 studies, comprising 40 participants to date, including 20 OTC deficient participants. The Company is preparing for meetings with the U.S. FDA and other regulatory agencies to discuss the clinical significance of the observed biomarker changes in relation to the design of the Phase 3 pivotal trial and pediatric studies. Phase 3 biomarker and trial design alignment with regulators is expected in first half of 2026. KOSTAIVE® regulatory updates include: A Marketing Authorization Application (MAA) filed by CSL to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in Q2 2025, approval expected by September 2025. NDA applications filed by Meiji Seika Pharma to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for the 2-dose lyophilized vaccine presentation in H1 2025, and the 2025-2026 season's SARS-CoV-2 variant update was completed in Q2 2025, with anticipated approvals in Q3/Q4 2025. U.S. BLA filing to the FDA remains on track for Q3 2025, with an approval decision expected in 2026. Under our collaboration with CSL Seqirus, we conducted a Phase 1 study (NCT06125691) of ARCT-2138, an sa-mRNA seasonal influenza vaccine candidate, encoding hemagglutinin (HA) and neuraminidase (NA) of 4 influenza strains recommended by the WHO. The clinical study report was finalized in June 2025. The study objectives were to evaluate the safety and tolerability and to describe the immune response of different dose levels of the vaccine in 100 young adults (18-49 years of age) and 35 older adults (≥ 65 years of age). All tested dose levels of ARCT-2138 were immunogenic against all four influenza strains as measured by hemagglutinin-inhibition assay in both age groups, demonstrating a modest dose-response (≤ 2.1-fold) within the range of the tested doses (2-20 μg). ARCT-2138 also induced NA-specific antibody responses at all tested dose levels of ARCT-2138 against all four influenza strains. The frequencies of unsolicited adverse events and medically attended adverse events were similar to comparator vaccines. No major safety concerns were raised from the study results. Overall, the study showed the potential of a self-amplifying mRNA vaccine, encoding eight antigens, to induce an immune response in both young and older adults with a dose as low as 2 μg, and tolerable up to 20 μg. The Company is expecting Phase 1 results in 2025 from ARCT-2304, an sa-mRNA vaccine candidate for Pandemic Influenza A Virus H5N1 which recently received U.S. FDA Fast Track Designation. No safety concerns were raised from available clinical data from the ongoing Phase 1 clinical study (NCT06602531) with 212 participants; all three tested dose levels (1.5, 5, and 12 µg) were well-tolerated, with the majority of the reported solicited AEs being mild-to-moderate severity and short-lived. Immunogenicity results are expected in Q4 2025. This project has been supported in whole with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50122C0007. The Company appointed Moncef Slaoui, Ph.D., as Chairman of the Board on July 1, 2025. Financial Results for the three months ended June 30, 2025 Revenues in conjunction with strategic alliances and collaborations: Arcturus' primary revenue streams include license fees, consulting and related technology transfer fees, reservation fees and collaborative payments received from research and development arrangements with pharmaceutical and biotechnology partners. Revenue for the three and six months ended June 30, 2025, was $28.3 million and $57.7 million, respectively, representing decreases of $21.6 million and $30.2 million compared to the same periods in 2024. These declines were primarily driven by reduced revenue from the CSL collaboration, reflecting lower supply agreement activity and lower amortization of the upfront payment as KOSTAIVE® progresses toward commercialization. Operating expenses: Total operating expenses for the three months ended June 30, 2025, were $39.9 million compared with $71.0 million for the three months ended June 30, 2024. Total operating expenses for the six months ended June 30, 2025, were $86.1 million compared with $139.4 million for the six months ended June 30, 2024. Research and development expenses: Research and development expenses consist primarily of external manufacturing costs, in vivo research studies and clinical trials performed by contract research organizations, clinical and regulatory consultants, personnel-related expenses, facility-related expenses and laboratory supplies related to conducting research and development activities. Research and development expenses were $29.6 million for the three months ended June 30, 2025, compared with $58.7 million for the three months ended June 30, 2024. The decrease was primarily driven by lower manufacturing costs for the KOSTAIVE, LUNAR-FLU, and cystic fibrosis programs, and reduced clinical trial expenses for KOSTAIVE and Ornithine Transcarbamylase Deficiency. Lower payroll and employee benefits also contributed to the decrease. These decreases were partially offset by higher clinical costs for cystic fibrosis following the start of Phase 2 trials in fiscal year 2025. Research and development expenses were $64.5 million for the six months ended June 30, 2025, compared with $112.2 million for the three months ended June 30, 2024. The decrease was primarily driven by lower manufacturing and clinical costs for the KOSTAIVE program, reflecting the program's transition from a development program to the commercial phase. Additional decreases resulted from lower payroll and benefits expenses and reduced facilities and equipment costs following the downsizing of operations. These reductions were partially offset by higher clinical expenses for the cystic fibrosis program. General and Administrative Expenses: General and administrative expenses primarily consist of salaries and related benefits for executive, administrative, legal and accounting functions and professional service fees for legal and accounting services as well as other general and administrative expenses. General and administrative expenses were $10.3 million and $21.7 million for the three and six months ended June 30, 2025, respectively, compared with $12.3 million and $27.2 million in the comparable periods last year. The decreases in both periods were primarily due to reduced share-based compensation expense as well as reduced payroll and benefits. We expect general and administrative expenses to continue to decrease slightly during the next twelve months driven by lower share-based compensation costs. Net Loss: For the three months ended June 30, 2025, Arcturus reported a net loss of approximately $9.2 million, or ($0.34) per diluted share, compared with a net loss of $17.2 million, or ($0.64) per diluted share in the three months ended June 30, 2024. For the six months ended June 30, 2025, Arcturus reported a net loss of approximately $23.3 million, or ($0.86) per diluted share, compared with a net loss of $44.0 million, or ($1.64) per diluted share in the six months ended June 30, 2024. Cash Position and Balance Sheet: Cash, cash equivalents and restricted cash were $253.4 million as of June 30, 2025, and $293.9 million on December 31, 2024. Based on the current pipeline and programs, the cash runway remains extended into 2028. Earnings Call: Monday, August 11, 2025 @ 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS Webcast: Link About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat OTC deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit In addition, please connect with us on X (formerly Twitter) and LinkedIn. Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success of the Company's pipeline (including ARCT-032 and ARCT-810) and partnered programs (including the COVID-19 and flu programs partnered with CSL Seqirus), the likelihood of and timing for providing interim data from the ARCT-032 Phase 2 CF study, the likelihood of and timing for completion of enrollment in the ARCT-032 Phase 2 CF study, the likelihood of and timing for Phase 3 trial design alignment with regulatory agencies for ARCT-810, the timing for Phase 1 results from the BARDA pandemic flu Phase 1 study, the likelihood of and timing for meetings with the FDA and other regulatory agencies relating to the CF and OTC programs, the likelihood of and timing for initiation of Phase 3 studies for the CF and OTC programs, the timing for completion of enrollment in the ARCT-032 (CF) Phase 2 study, the likelihood of and timing for approval of the MAA on KOSTAIVE filed by CSL to the UK MHRA, the likelihood and timing for approvals of NDA applications for KOSTAIVE filed by Meiji Seika Pharma with Japan's PMDA, the planned U.S. BLA filing and expected approval decision for KOSTAIVE, efforts for optimization and testing for seasonal influenza program, the timing for Phase 1 results for the pandemic influenza vaccine candidate, the likelihood that general and administrative expenses will decrease, the likelihood that preclinical or clinical data will be predictive of future clinical results, its current cash position and expected cash burn and runway, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus' most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC's website at Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES (unaudited) June 30, June 30, (in thousands, except per share data) 2025 2024 2025 2024 Revenue: Collaboration revenue $ 24,510 $ 45,976 $ 49,987 $ 78,574 Grant revenue 3,791 3,883 7,696 9,297 Total revenue 28,301 49,859 57,683 87,871 Operating expenses: Research and development, net 29,579 58,669 64,471 112,242 General and administrative 10,338 12,316 21,654 27,167 Total operating expenses 39,917 70,985 86,125 139,409 Loss from operations (11,616 ) (21,126 ) (28,442 ) (51,538 ) Loss from foreign currency (127 ) (388 ) (149 ) (441 ) Finance income, net 2,567 4,148 5,339 8,164 Net loss before income taxes (9,176 ) (17,366 ) (23,252 ) (43,815 ) Provision (benefit) for income taxes 4 (150 ) 4 218 Net loss $ (9,180 ) $ (17,216 ) $ (23,256 ) $ (44,033 ) Net loss per share, basic and diluted $ (0.34 ) $ (0.64 ) $ (0.86 ) $ (1.64 ) Weighted-average shares outstanding, basic and diluted 27,129 26,967 27,118 26,923 Comprehensive loss: Net loss $ (9,180 ) $ (17,216 ) $ (23,256 ) $ (44,033 ) Comprehensive loss $ (9,180 ) $ (17,216 ) $ (23,256 ) $ (44,033 ) Expand
Yahoo
3 hours ago
- Yahoo
Kapa Gold Announces Warrant Expiry Date Acceleration
Vancouver, British Columbia--(Newsfile Corp. - August 11, 2025) - KAPA GOLD INC. (TSXV: KAPA) ("Kapa" or the "Company") announces that the Company has elected to accelerate the expiry date of certain outstanding common share purchase warrants of the Company ("Warrants"), originally issued in connection with the closing of a private placement on May 19, 2022 (the "Financing"). The exercise price and expiry date of the Warrants were subsequently amended on April 8, 2024 (the "Amendments"). Pursuant to the Amendments, the Company may accelerate the expiry date of the Warrants if the closing price of the Company's common shares ("Shares") on the TSX Venture Exchange (the "TSXV") equals or exceeds C$0.25 for ten (10) consecutive trading days, to the date which is thirty (30) days following the dissemination of a news release announcing the acceleration (the "Acceleration"). As the closing price of the Shares on the TSXV has equaled or exceeded C$0.25 over each of the last ten (10) trading days ended August 7, 2025, the Company hereby provides notice of the Acceleration in accordance with the Amendments. The Company is exercising its right to accelerate the expiry date of the Warrants originally issued under the Financing to 5:00 pm (Vancouver Time) on September 10, 2025 (the "Accelerated Expiry Date"). Any Warrants remaining unexercised after the Accelerated Expiry Date will expire and be of no force and effect. The Company intends to use proceeds from the exercise of the Warrants for general administrative and working capital purposes. There is no assurance that any or all of the Warrants will be exercised. Holders may exercise the Warrants before the Accelerated Expiry Date by observing the process as described in the Warrant certificates. About Blackhawk Gold Project Blackhawk Gold Project is located in the historic Blackhawk Mining District in California, a region renowned for its gold and silver production. The mine has a long history of precious metal extraction, with several high-potential exploration targets identified. Kapa Gold is focusing on establishing a resource and developing a sustainable extraction strategy using modern techniques. About Kapa Gold Kapa Gold Inc. is a Canadian exploration company focused on advancing its portfolio of high-potential gold projects in North America. The Company's flagship project, the Blackhawk Gold Property, aims to deliver significant shareholder value through strategic exploration and development initiatives. Kapa Gold is dedicated to responsible mining, sustainable growth, and contributing positively to the communities in which it operates. To learn more, visit On behalf of the Board of Directors KAPA GOLD INC."David K. Paxton"CEO and Director For More Information Contact:Konstantine Tsakumiskon@ THIS PRESS RELEASE, PROVIDED PURSUANT TO APPLICABLE CANADIAN REQUIREMENTS, IS NOT FOR DISTRIBUTION TO UNITED STATES NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information Certain statements made, and information contained herein may constitute "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation. These statements and information are based on facts currently available to the Company and there is no assurance that actual results will meet management's expectations. Forward-looking statements and information may be identified by such terms as "anticipates", "believes", "targets", "estimates", "plans", "expects", "may", "will", "could" or "would". Forward-looking statements and information contained herein are based on certain factors and assumptions. While the Company considers its assumptions to be reasonable as of the date hereof, forward-looking statements and information are not guaranteeing of future performance and readers should not place undue importance on such statements as actual events and results may differ materially from those described herein. The Company does not undertake to update any forward-looking statements or information except as may be required by applicable securities laws. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
7 hours ago
- Business Wire
LibertyStream and Wellspring Hydro Announce US $700,000 Grant to Fund Lithium Refining Unit backed by State of North Dakota; Proceeds Drawn From US$7.5 million pre-Approved State Funded Grant and Loan Facility
CALGARY, Alberta--(BUSINESS WIRE)-- LibertyStream Infrastructure Partners Inc. (TSXV: LIB | OTCQB: VLTLF | FSE: I2D) (' LibertyStream ' or the ' Company ') is pleased to announce the Company has been awarded a US$700,000 grant to fund a portion of the previously announced commercial lithium carbonate refining unit (the ' Refining Unit ') capable of producing up to 10 tonnes per annum (tpa) of industrial grade and battery grade lithium carbonate. This follow-on support comes via LibertyStream's partnership with Wellspring Hydro ('WSH') and is consistent with the state's commitment to accelerating critical minerals development within the U.S. The proceeds from the grant are drawn from Wellspring's US$10 million North Dakota State backed grant and loan facility of which US$4.2 million is available for future drawdown. ' We are deeply grateful to the State of North Dakota for this continued support, which not only reflects confidence in our DLE technology but also underscores our shared goal of strengthening the domestic supply chain for critical minerals, ' commented Alex Wylie, President & CEO of LibertyStream. 'Customers have made it clear they require bulk lithium carbonate samples to negotiate future offtake agreements. The Refining Unit is expected to provide our future customers with the lithium carbonate from the field they require.' US $7.5 Million North Dakota State Funded Facility Wellspring was previously awarded US$7.5 million in grant and loan funding from the North Dakota Industrial Commission through the Clean Sustainable Energy Authority Program and the Renewable Energy Program (collectively, the 'State Funding'). LibertyStream and Wellspring have utilized the State Funding to advance DLE initiatives within the State of North Dakota. Following the US$700,000 drawdown, approximately US$4.2 million remains available for future deployment. The State Funding is intended to promote the adoption of renewable energy technologies, support businesses operating in North Dakota, and leverage the capabilities of the local workforce. Initially, the Refining Unit will be deployed at LibertyStream's facility in Texas, with plans to relocate it to North Dakota upon completion of commercial DLE facility development in the Williston Basin. LibertyStream and Wellspring anticipate drawing the remaining US$4.2 million in State Funding to further support the build-out of these commercial DLE operations in North Dakota. Lithium Carbonate Refining Unit The Refining Unit will be capable of producing up to 10 tpa of lithium carbonate tailored to the technical specifications of future customers for either industrial grade or battery grade lithium carbonate. In order to have the ability to sign offtake agreements, future customers need bulk sample from the field. Management anticipates that the Refining Unit will consistently provide its customers with the confidence to rely on the grade and quality of lithium carbonate for future offtake agreements. Corporate Secretary Appointment LibertyStream is pleased to announce the appointment of Eamon Hurley as Corporate Secretary for the Company. Mr. Hurley is a Partner at Cassels Brock & Blackwell LLP ('Cassels') and was former Canadian General Counsel to Unocal Corporation. Cassels acts as Corporate Counsel to the Company. The Company is granting Mr. Hurley 250,000 options under its omnibus equity incentive plan. The Options vest over a six-month period and are exercisable at $0.23 per Share for four years from the date of grant, expiring on August 11, 2029. About LibertyStream Infrastructure Partners LibertyStream is a lithium development and technology company aiming to be one of North America's first commercial producers of lithium carbonates from oilfield brine. Our strategy is to generate value for shareholders by leveraging management's hydrocarbon experience to deploy our proprietary DLE technology directly into existing oil and gas infrastructure, thereby reducing capital costs, lowering risks and supporting the world's clean energy transition. With four differentiating pillars, and a proprietary DLE technology and process, LibertyStream's innovative approach to development is focused on generating the highest lithium recoveries with lowest costs, positioning us for future commercialization. We are committed to operating efficiently and with transparency across all areas of the business staying sharply focused on creating long-term, sustainable shareholder value. Investors and/or other interested parties may sign up for updates about the Company's continued progress on its website: Forward Looking Statements This news release includes certain 'forward-looking statements' and 'forward-looking information' within the meaning of applicable Canadian securities laws. When used in this news release, the words 'anticipate', 'believe', 'estimate', 'expect', 'target', 'plan', 'forecast', 'may', 'will', 'would', 'could', 'schedule' and similar words or expressions, identify forward-looking statements or information. Statements, other than statements of historical fact, may constitute forward-looking information and include, without limitation, management's expectations relating to the processing capacity of its DLE unit, information with respect to the completion and timing of the purchase of the Refining Unit and expectations of production therefrom, the anticipated benefits to the Company's customers relating to the deployment of the Refining Unit. With respect to the forward-looking information contained in this press release, the Company has made numerous assumptions. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies and may prove to be incorrect. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein including the risk of delay in completing the purchase of the Refining Unit, the risk that management's production estimates relating to the Refining Unit turn out to be incorrect, and generally, those known risk factors outlined in the Company's annual information form for the year ended June 30, 2024, the Management's Discussion and Analysis for the six months ended December 31, 2024, and the (final) short form base shelf prospectus dated July 20, 2023. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
